Close Menu

NEW YORK – Danaher reported on Thursday a 6 percent year-over-year increase in total sales for the fourth quarter, beating the consensus Wall Street estimate.

For the three months ended Dec. 31, 2019, the Washington, DC-based conglomerate posted $4.87 billion in total sales compared to $4.60 billion in the year-ago period. Analysts' average estimate was for $4.80 billion.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Public health experts call for a transparent COVID-19 vaccine approval process in a letter; the Food and Drug Administration commissioner assures science-based approval.

The Verge reports that new gene-naming guidelines aim in part to avoid Excel-related name change confusion.

In Nature this week: tuatara genome sequence aids in understanding amniote evolution, and more.

According to the Guardian, UK virologists say in a letter to officials that their expertise has been pushed aside in COVID-19 response plans.